Xortx Therapeutics Stock Performance
| XRTX Stock | 1.73 0.15 7.98% |
XORTX Therapeutics holds a performance score of 5 on a scale of zero to a hundred. The firm maintains a market beta of 2.34, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, XORTX Therapeutics will likely underperform. Use XORTX Therapeutics maximum drawdown, semi variance, accumulation distribution, as well as the relationship between the potential upside and skewness , to analyze future returns on XORTX Therapeutics.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in XORTX Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, XORTX Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:9 | Last Split Date 2023-11-14 |
1 | XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders - GlobeNewswire | 09/06/2024 |
2 | XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks | 11/15/2024 |
| Begin Period Cash Flow | 10.4 M |
XORTX |
XORTX Therapeutics Relative Risk vs. Return Landscape
If you would invest 154.00 in XORTX Therapeutics on August 28, 2024 and sell it today you would earn a total of 19.00 from holding XORTX Therapeutics or generate 12.34% return on investment over 90 days. XORTX Therapeutics is generating 1.2668% of daily returns assuming 18.7077% volatility of returns over the 90 days investment horizon. Simply put, majority of traded equity instruments are less risky than XORTX on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
XORTX Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XORTX Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XORTX Therapeutics, and traders can use it to determine the average amount a XORTX Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0677
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | XRTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 18.71 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.27 actual daily | 25 75% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average XORTX Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XORTX Therapeutics by adding it to a well-diversified portfolio.
XORTX Therapeutics Fundamentals Growth
XORTX Stock prices reflect investors' perceptions of the future prospects and financial health of XORTX Therapeutics, and XORTX Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XORTX Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 2.45 M | ||||
| Shares Outstanding | 3.22 M | ||||
| Price To Book | 1.87 X | ||||
| EBITDA | (3.3 M) | ||||
| Net Income | (2.16 M) | ||||
| Total Debt | 825.94 K | ||||
| Book Value Per Share | 2.32 X | ||||
| Cash Flow From Operations | (6.58 M) | ||||
| Earnings Per Share | 0.17 X | ||||
| Market Capitalization | 5.58 M | ||||
| Total Asset | 5.47 M | ||||
| Retained Earnings | (17.85 M) | ||||
| Working Capital | 3.77 M | ||||
About XORTX Therapeutics Performance
Evaluating XORTX Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if XORTX Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if XORTX Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (590.60) | (620.13) | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.94) | (0.89) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.47) | (0.49) |
Things to note about XORTX Therapeutics performance evaluation
Checking the ongoing alerts about XORTX Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XORTX Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XORTX Therapeutics is way too risky over 90 days horizon | |
| XORTX Therapeutics may become a speculative penny stock | |
| XORTX Therapeutics appears to be risky and price may revert if volatility continues | |
| XORTX Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XORTX Therapeutics generates negative cash flow from operations | |
| Latest headline from news.google.com: XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks |
- Analyzing XORTX Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XORTX Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining XORTX Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XORTX Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of XORTX Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XORTX Therapeutics' stock. These opinions can provide insight into XORTX Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.